What is the dosing range for Survodutide?

Survodutide is typically dosed at 0.3mg (low), 3mg (moderate), or 6mg (high) mg, administered once weekly subcutaneous. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of Survodutide?

Reported side effects of Survodutide include: Nausea (dose-dependent, during titration), Vomiting, Diarrhea, Decreased appetite, Injection site reactions, Transient heart-rate increase (glucagon-related — under study).

GLP-1

Survodutide

Also known as: BI 456906, Glucagon/GLP-1 dual agonist, Zealand/Boehringer dual agonist

Share:Share on Reddit

Reviewed by the Research Stack Editorial TeamLast reviewed August 3, 20262 peer-reviewed sources

Survodutide is an investigational compound and is NOT FDA-approved. Phase 3 efficacy figures cited are topline results from the sponsor, not full peer-reviewed publications. For research and educational purposes only — not medical advice.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. It pairs GLP-1's appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation — a mechanism especially promising for fatty-liver disease. It is not FDA-approved.

Research Summary

Survodutide activates both the glucagon receptor (increasing energy expenditure and liver fat oxidation) and the GLP-1 receptor (reducing appetite and slowing gastric emptying). Its Phase 3 SYNCHRONIZE-1 obesity trial met its primary endpoint with meaningful weight loss at 76 weeks, and survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis. As of mid-2026 it remains investigational, with efficacy figures at the topline/conference stage.

Dosing Range

low

0.3mg

moderate

3mg

high

6mg

Units: mg · Frequency: once weekly subcutaneous

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injection (weekly)

Reconstitution Notes

Clinical-trial material is delivered via prefilled pen under a slow titration schedule. Survodutide is investigational — no pharmaceutical-grade product is publicly available. Any research material is not quality-controlled for human use.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Nausea (dose-dependent, during titration)
Vomiting
Diarrhea
Decreased appetite
Injection site reactions
Transient heart-rate increase (glucagon-related — under study)

Research Papers

2 peer-reviewed sources

Phase III SYNCHRONIZE-1 obesity trial met its primary endpoint (Boehringer Ingelheim)

Boehringer Ingelheim (topline release)2026

Survodutide weight-loss and metabolic data — glucagon/GLP-1 dual agonism

Boehringer Ingelheim2026

Latest Survodutide Research

Most recent publications from PubMed, refreshed daily. Automatically retrieved — not editorially curated.

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Peptides

Community discussion tracking survodutide's trial readouts and its MASH/liver-fat positioning.

View original thread

Overview

Survodutide (development code BI 456906) is an investigational once-weekly peptide that activates two receptors: the glucagon receptor and the GLP-1 receptor. It is being co-developed by Boehringer Ingelheim and Zealand Pharma for obesity and, notably, for metabolic dysfunction-associated steatohepatitis (MASH) — the more advanced, inflammatory form of fatty-liver disease.

Mechanism: Why the Glucagon Arm Matters

Most first-generation weight-loss drugs (semaglutide) act on GLP-1 alone. Survodutide adds glucagon-receptor agonism, and the two arms attack the energy-balance equation from different sides:

GLP-1 — reduces appetite, slows gastric emptying, improves glucose-dependent insulin secretion
Glucagon — increases energy expenditure and drives hepatic fat oxidation (burning liver fat)

The glucagon component is what makes survodutide especially interesting for the liver. Where GLP-1 mono-agonists reduce liver fat mainly through weight loss, adding glucagon agonism targets hepatic fat more directly — the rationale behind its MASH program.

Clinical Data

Obesity — SYNCHRONIZE-1 (Phase 3). Survodutide's pivotal obesity trial met its primary endpoint, with meaningful weight loss reported at 76 weeks. As of mid-2026 the detailed results are at the topline/conference stage rather than full peer-reviewed publication.

Liver disease — MASH. Survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis, reflecting strong earlier-phase liver-fat and fibrosis signals. This positions it as a candidate not just for weight loss but as a potential MASH therapy — a large unmet need.

How It Fits the Landscape

| Agent | Receptors | Status | |---|---|---| | Semaglutide | GLP-1 | Approved | | Tirzepatide | GIP + GLP-1 | Approved | | Survodutide | Glucagon + GLP-1 | Investigational (Phase 3) | | Retatrutide | GIP + GLP-1 + glucagon | Investigational (Phase 3) |

Survodutide and retatrutide both harness glucagon agonism, but survodutide pairs it with GLP-1 only (a dual agonist), while retatrutide adds GIP as well (a triple agonist). Survodutide's distinct emphasis is its MASH/liver positioning.

Research Notes

All human efficacy data are industry-sponsored and, for Phase 3, currently topline. The glucagon component means cardiovascular and heart-rate effects warrant monitoring, as with other glucagon-containing agonists. Because survodutide is investigational, any non-trial material is by definition not pharmaceutical-grade.